A Phase 2 interventional study of Ublituximab and Umbralisib in Chronic Lymphocytic Leukemia, sponsored by TG Therapeutics, Inc.. Terminated at 87 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-22.
Sponsored by TG Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell — none open to participants now, 1 under way, none of them phase 3. ublituximab · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 5th largest by enrollment, is the only one that started in 2016, is one of 5 in phase 2, and was the 8th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →None of the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell is open now. The open studies under Leukemia, Lymphocytic, Chronic, B-Cell, anywhere →
ublituximab: first FDA approval 2022 (BRIUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 3
First in 2008; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 116 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 51 across the 13 interventional studies. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 4 most frequent:
TG Therapeutics, Inc. is the lead sponsor of 40 studies on the registry; 9 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by TG Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 18 finished, 7 (39%) have results posted.
Among the 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by TG Therapeutics, Inc., this one is the 7th largest by enrollment, is one of 3 that started in 2016, is one of 5 in phase 2, and was the 10th registered.
TG Therapeutics, Inc.’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among TG Therapeutics, Inc.’s 18 in Leukemia, Lymphocytic, Chronic, B-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to provide the opportunity to the participants who progressed on treatment arm previously in the study UTX-TGR-304 (NCT02612311) to receive ublituximab (TG-1101) treatment in combination with umbralisib (TGR-1202).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants from Arm B of the parent trial (UTX-TGR-304) received ublituximab, 150 milligrams (mg), intravenously (IV), on Day 1, 750 mg on Day 2, followed by 900 mg on Days 8 and 15 of Cycle 1 (cycle length=28 days), Day 1 of Cycles 2-6, and once every 3 months thereafter, along with umbralisib, 800 mg, orally, once daily during each cycle until disease progression, lack of tolerability, or until the treatment is commercially available or up to 78 months.
Biological: Ublituximab · Drug: Umbralisib
Participants from Arm C of the parent trial (UTX-TGR-304) received ublituximab, 900 mg, IV, on Day 1 of Cycles 1-6 (cycle length=28 days), and once every 3 months thereafter, along with umbralisib, 800 mg, orally, once daily during each cycle until disease progression, lack of tolerability, or until the treatment is commercially available or up to 78 months.
Biological: Ublituximab · Drug: Umbralisib
Participants from Arm D of the parent trial (UTX-TGR-304) received ublituximab, 150 mg, IV, on Day 1, 750 mg on Day 2, followed by 900 mg on Days 8 and 15 of Cycle 1 (cycle length=28 days), Day 1 of Cycles 2-6, and once every 3 months thereafter, along with umbralisib, 800 mg, orally, once daily during each cycle until disease progression, lack of tolerability, or until the treatment is commercially available or up to 78 months.
Biological: Ublituximab · Drug: Umbralisib
Ublituximab IV infusion
Also known as: TG-1101
Umbralisib tablets
Also known as: TGR-1202
Overall Response Rate (ORR) as Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria
ORR was defined as sum of participants with partial responses (PR) and complete responses (CR). CR: No evidence of new disease; Absolute lymphocyte count(ALC)\<4x10\^9/liter(L); Regression of all target nodal masses to ≤1.5 centimeters (cm) in longest diameter(LD); Normal spleen,liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; Absolute neutrophil count(ANC)\>1.5x10\^9/L,platelets≥100x10\^9/L,hemoglobin (Hgb)≥110 gram per liter(g/L). PR: No evidence of new disease; Response in 2 of following if abnormal at baseline: ALC\<4x10\^9/L or ≥50% decrease from baseline in sum of products(SPD) of target nodal lesions; splenomegaly; hepatomegaly;≥50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules; response in any 1:ANC\>1.5x10\^9/L,platelets\>100x10\^9/L,Hgb\>110g/L or ≥50% increase over baseline in any of these.
Time frame: Up to 76 months
Complete Response (CR) Rate Per iwCLL Criteria
The CR rate was defined as the percentage of participants who achieved CR. CR: No evidence of new disease; ALC \<4 x 10\^9/L; Regression of all target nodal masses to normal size ≤1.5 cm in the LD; Normal spleen and liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; ANC \>1.5 x 10\^9/L, platelets ≥100 x 10\^9/L, Hgb ≥110 g/L.
Time frame: Up to 76 months
Progression-Free Survival (PFS) Per iwCLL Criteria
PFS was defined as the interval from enrollment to the earlier of the first documentation of definitive disease progression (PD) or death from any cause. PD was appearance of new nodes \>1.5 cm in the LD and \>1.0 in longest perpendicular diameter (LPD), new or recurrent hepatomegaly or splenomegaly, new or reappearance of an unequivocal extra-nodal lesion, ≥50% increase from the nadir in the sum of products of diameters (SPD) of target lesions, ≥50% increase in the LD of an individual node or extra-nodal mass, splenic/hepatic enlargement of ≥50% from nadir, unequivocal increase in the size of non-target disease, transformation to a more aggressive histology, decrease in platelet count or Hgb, \>50% decrease from the highest on-study platelet count, \>20 g/L decrease from the highest on-study Hgb.
Time frame: Up to 76 months
Duration of Response (DOR)
DOR:Interval from first documentation of CR/PR to first documentation of PD or death from any cause.CR:ALC\<4x10\^9/L;Regression to normal of target nodal masses,nodal non-target disease,and no detectable non-nodal,non-target disease;Normal spleen,liver size;Morphologically negative bone marrow,No lymphoid nodules;ANC\>1.5x10\^9/L,Platelets≥100x10\^9/L,Hgb≥110 g/L.PR:Response in 2 or more:ALC\<4x10\^9/L, ≥50% drop from baseline in ALC or SPD of target nodal lesions,Hepatosplenomegaly,≥50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules;Response in 1 or more:ANC\>1.5x10\^9/L,Platelets\>100x10\^9/L,Hgb\>110 g/L or ≥50% increase over baseline in any.PD:Response in 1 or more:new nodes,Hepatosplenomegaly,unequivocal extra-nodal lesion;≥50% increase from nadir in SPD of target lesions or LD of node/extra-nodal mass or Splenic/Hepatic size,Unequivocal increase in non-target disease,More aggressive histology;Drop of \>50% in platelets/\>20g/L in Hgb from highest on-study count.
Time frame: Up to 76 months
Minimal Residual Disease (MRD) Negativity Rate
MRD negativity rate is defined as the percentage of participants who are MRD negative. If a participant was determined to be MRD negative by peripheral blood, a bone marrow aspirate was obtained to assess MRD in the bone marrow.
Time frame: From Cycle 6 until Cycle 15 (cycle length=28 days) (Up to approximately 76 months)
Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product. An AE does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is any AE that occur after first dosing of study medication and through the end of the study or through 30 days after the last dose of study treatment, or is considered treatment-related regardless of the start date of the event, or is present before first dosing of study medication but worsens in intensity or the investigator subsequently considers treatment-related.
Time frame: Up to 78 months
A total of 116 participants took part across 50 investigative sites in the United States, United Kingdom, Italy, and Poland from 07 January 2016 to 11 July 2022.
| Milestone | Parent Study Arm B | Parent Study Arm C | Parent Study Arm D |
|---|---|---|---|
| Started | 67 | 31 | 18 |
| Completed | 0 | 0 | 0 |
| Not completed | 67 | 31 | 18 |
| Withdrew: Adverse event | 3 | 2 | 0 |
| Withdrew: Death | 12 | 4 | 1 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 |
| Withdrew: Non-compliance with study | 1 | 1 | 0 |
| Withdrew: Investigator decision | 2 | 1 | 0 |
| Withdrew: Progressive disease | 25 | 14 | 10 |
| Withdrew: Study terminated by sponsor | 20 | 7 | 5 |
| Withdrew: Withdrawal of consent by participants | 1 | 1 | 0 |
| Withdrew: Initiation of non-protocol intervention | 1 | 0 | 0 |
| Withdrew: Reason not specified | 1 | 1 | 2 |
ORR was defined as sum of participants with partial responses (PR) and complete responses (CR). CR: No evidence of new disease; Absolute lymphocyte count(ALC)\<4x10\^9/liter(L); Regression of all target nodal masses to ≤1.5 centimeters (cm) in longest diameter(LD); Normal spleen,liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; Absolute neutrophil count(ANC)\>1.5x10\^9/L,platelets≥100x10\^9/L,hemoglobin (Hgb)≥110 gram per liter(g/L). PR: No evidence of new disease; Response in 2 of following if abnormal at baseline: ALC\<4x10\^9/L or ≥50% decrease from baseline in sum of products(SPD) of target nodal lesions; splenomegaly; hepatomegaly;≥50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules; response in any 1:ANC\>1.5x10\^9/L,platelets\>100x10\^9/L,Hgb\>110g/L or ≥50% increase over baseline in any of these.
No measurements were reported for this outcome.
The CR rate was defined as the percentage of participants who achieved CR. CR: No evidence of new disease; ALC \<4 x 10\^9/L; Regression of all target nodal masses to normal size ≤1.5 cm in the LD; Normal spleen and liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; ANC \>1.5 x 10\^9/L, platelets ≥100 x 10\^9/L, Hgb ≥110 g/L.
No measurements were reported for this outcome.
PFS was defined as the interval from enrollment to the earlier of the first documentation of definitive disease progression (PD) or death from any cause. PD was appearance of new nodes \>1.5 cm in the LD and \>1.0 in longest perpendicular diameter (LPD), new or recurrent hepatomegaly or splenomegaly, new or reappearance of an unequivocal extra-nodal lesion, ≥50% increase from the nadir in the sum of products of diameters (SPD) of target lesions, ≥50% increase in the LD of an individual node or extra-nodal mass, splenic/hepatic enlargement of ≥50% from nadir, unequivocal increase in the size of non-target disease, transformation to a more aggressive histology, decrease in platelet count or Hgb, \>50% decrease from the highest on-study platelet count, \>20 g/L decrease from the highest on-study Hgb.
No measurements were reported for this outcome.
DOR:Interval from first documentation of CR/PR to first documentation of PD or death from any cause.CR:ALC\<4x10\^9/L;Regression to normal of target nodal masses,nodal non-target disease,and no detectable non-nodal,non-target disease;Normal spleen,liver size;Morphologically negative bone marrow,No lymphoid nodules;ANC\>1.5x10\^9/L,Platelets≥100x10\^9/L,Hgb≥110 g/L.PR:Response in 2 or more:ALC\<4x10\^9/L, ≥50% drop from baseline in ALC or SPD of target nodal lesions,Hepatosplenomegaly,≥50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules;Response in 1 or more:ANC\>1.5x10\^9/L,Platelets\>100x10\^9/L,Hgb\>110 g/L or ≥50% increase over baseline in any.PD:Response in 1 or more:new nodes,Hepatosplenomegaly,unequivocal extra-nodal lesion;≥50% increase from nadir in SPD of target lesions or LD of node/extra-nodal mass or Splenic/Hepatic size,Unequivocal increase in non-target disease,More aggressive histology;Drop of \>50% in platelets/\>20g/L in Hgb from highest on-study count.
No measurements were reported for this outcome.
MRD negativity rate is defined as the percentage of participants who are MRD negative. If a participant was determined to be MRD negative by peripheral blood, a bone marrow aspirate was obtained to assess MRD in the bone marrow.
No measurements were reported for this outcome.
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product. An AE does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is any AE that occur after first dosing of study medication and through the end of the study or through 30 days after the last dose of study treatment, or is considered treatment-related regardless of the start date of the event, or is present before first dosing of study medication but worsens in intensity or the investigator subsequently considers treatment-related.
| Participants | Parent Study Arm B | Parent Study Arm C | Parent Study Arm D |
|---|---|---|---|
| Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE) | 66 | 30 | 18 |
Collected over Up to approximately 78 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Parent Study Arm B | 23/67 (34.3%) | 36/67 (53.7%) | 65/67 (97%) |
| Parent Study Arm C | 9/31 (29%) | 13/31 (41.9%) | 30/31 (96.8%) |
| Parent Study Arm D | 7/18 (38.9%) | 8/18 (44.4%) | 17/18 (94.4%) |
| Event | Parent Study Arm B | Parent Study Arm C | Parent Study Arm D |
|---|---|---|---|
| PneumoniaInfections and infestations | 8/67 | 2/31 | 1/18 |
| COVID-19Infections and infestations | 4/67 | 1/31 | 2/18 |
| COVID-19 pneumoniaInfections and infestations | 5/67 | 2/31 | 2/18 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/67 | 0/31 | 2/18 |
| Aspergillus infectionInfections and infestations | 0/67 | 0/31 | 1/18 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/67 | 0/31 | 1/18 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/67 | 0/31 | 1/18 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/67 | 0/31 | 1/18 |
| HypertensionVascular disorders | 0/67 | 0/31 | 1/18 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/67 | 0/31 | 0/18 |
| Event | Parent Study Arm B | Parent Study Arm C | Parent Study Arm D |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 35/67 | 11/31 | 6/18 |
| Infusion related reactionInjury, poisoning and procedural complications | 15/67 | 5/31 | 9/18 |
| NauseaGastrointestinal disorders | 29/67 | 10/31 | 5/18 |
| FatigueGeneral disorders | 23/67 | 12/31 | 2/18 |
| NeutropeniaBlood and lymphatic system disorders | 17/67 | 6/31 | 6/18 |
| CoughRespiratory, thoracic and mediastinal disorders | 22/67 | 5/31 | 3/18 |
| Upper respiratory tract infectionInfections and infestations | 14/67 | 9/31 | 4/18 |
| Neutrophil count decreasedInvestigations | 3/67 | 3/31 | 5/18 |
| InsomniaPsychiatric disorders | 16/67 | 5/31 | 3/18 |
| Alanine aminotransferase increasedInvestigations | 15/67 | 6/31 | 3/18 |
The Safety Population included all participants who were enrolled and received at least one dose of study drug.
| Age, Continuous(years) | Parent Study Arm B | Parent Study Arm C | Parent Study Arm D | Total |
|---|---|---|---|---|
| Mean | 65.6 ± 8.18 | 66.7 ± 9.41 | 65.7 ± 8.79 | 65.9 ± 8.55 |
| Sex: Female, Male(Participants) | Parent Study Arm B | Parent Study Arm C | Parent Study Arm D | Total |
|---|---|---|---|---|
| Female | 19 | 5 | 5 | 29 |
| Male | 48 | 26 | 13 | 87 |
| Ethnicity (NIH/OMB)(Participants) | Parent Study Arm B | Parent Study Arm C | Parent Study Arm D | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 2 |
| Not Hispanic or Latino | 66 | 30 | 16 | 112 |
| Unknown or Not Reported | 0 | 1 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Parent Study Arm B | Parent Study Arm C | Parent Study Arm D | Total |
|---|---|---|---|---|
| Race — White | 65 | 30 | 15 | 110 |
| Race — Black or African American | 2 | 0 | 1 | 3 |
| Race — Other | 0 | 0 | 2 | 2 |
| Race — Not Reported | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2016 to primary completion in May 2022, 76 months.
Results were first posted in Jun 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ublituximab · Umbralisib
Leukemia, Lymphocytic, Chronic, B-Cell →